Publications by authors named "Daniel P Petrylak"

100Publications

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.

N Engl J Med 2020 09 18;383(13):1218-1230. Epub 2020 Sep 18.

From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2002788DOI Listing
September 2020

When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.

Eur Urol Oncol 2020 10 17;3(5):594-611. Epub 2020 Aug 17.

Smilow Cancer Center, Yale University, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2020.07.005DOI Listing
October 2020

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

J Clin Oncol 2020 Aug 9;38(24):2798-2811. Epub 2020 Jun 9.

Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.20.00046DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430215PMC
August 2020

Reply to F.E. Vera-Badillo et al.

J Clin Oncol 2020 02 27;38(6):651-652. Epub 2019 Dec 27.

Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY; and Daniel P. Petrylak, MD, Yale Cancer Center, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.02830DOI Listing
February 2020

Atezolizumab in understudied populations with bladder cancer.

Nat Rev Urol 2019 Aug;16(8):449-450

Yale Cancer Center, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-019-0200-8DOI Listing
August 2019

Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.

Cell 2018 08 9;174(5):1200-1215.e20. Epub 2018 Aug 9.

Cancer Biology Department, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA; Medical Oncology Department, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA; Pathology Department, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2018.07.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150493PMC
August 2018

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.

J Clin Oncol 2018 06 28;36(16):1579-1587. Epub 2018 Mar 28.

David J. Vaughn, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA; Yves Fradet, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; Jae Lyun Lee, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Republic of Korea; Lawrence Fong, University of California, San Francisco, San Francisco; David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Miguel A. Climent, Fundación Instituto Valenciano de Oncología, Valencia, Spain; Daniel P. Petrylak, Smilow Cancer Hospital, Yale University, New Haven, CT; Andrea Necchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan; Cora N. Sternberg, San Camillo and Forlanini Hospitals, Rome, Italy; Winald Gerritsen, Radboud University Medical Center, Nijmegen; Ronald de Wit, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands; Howard Gurney, Westmead Hospital and Macquarie University, Sydney, New South Wales, Australia; Stephane Culine, Hôpital Saint-Louis, Paris, France; Yabing Mai, Haojie Li, and Rodolfo F. Perini, Merk & Co., Inc., Kenilworth, NJ; and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.9562
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.9562DOI Listing
June 2018

Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes.

Lancet Oncol 2018 01;19(1):23-24

Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30916-6DOI Listing
January 2018

Introduction to the Yale Precision Medicine Tumor Board.

Lancet Oncol 2018 01;19(1):19-20

Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT 06520, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30919-1DOI Listing
January 2018

Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer.

Clin Genitourin Cancer 2018 04 24;16(2):e469-e476. Epub 2017 Oct 24.

Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Prostate and Urological Cancers Program, Yale Comprehensive Cancer Center, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.10.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878980PMC
April 2018

Immunotherapy: The Wave of the Future in Bladder Cancer?

Clin Genitourin Cancer 2017 06;15(3S):S3-S17

Department of Medical Oncology, Yale University, New Haven, CT. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.05.025DOI Listing
June 2017

Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.

Target Oncol 2017 08;12(4):401-412

University of Colorado School of Medicine, Aurora, CO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-017-0500-yDOI Listing
August 2017

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.

Ther Adv Med Oncol 2017 May 22;9(5):319-333. Epub 2017 Mar 22.

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834017698644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424866PMC
May 2017

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

N Engl J Med 2017 03 17;376(11):1015-1026. Epub 2017 Feb 17.

From Dana-Farber Cancer Institute, Boston (J.B., T.K.C.); Parc de Salut Mar, Hospital del Mar Medical Research Institute, Barcelona (J.B.), and Fundación Instituto Valenciano de Oncología, Valencia (M.A.C.) - both in Spain; Erasmus MC Cancer Institute, Rotterdam (R.W.), and Radboud University Medical Center, Nijmegen (W.G.) - both in the Netherlands; Abramson Cancer Center, University of Pennsylvania, Philadelphia (D.J.V.); Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, QC, Canada (Y.F.); Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea (J.-L.L.); the University of California, San Francisco, San Francisco (L.F.); Comprehensive Cancer Centers of Nevada, Las Vegas (N.J.V.); Smilow Cancer Hospital, Yale University, New Haven, CT (D.P.P.); Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (A.N.); Westmead Hospital and Macquarie University, Sydney (H.G.); the University of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles (D.I.Q.); Hôpital Saint-Louis, Paris (S.C.); San Camillo and Forlanini Hospitals, Rome (C.N.S.); Merck, Kenilworth, NJ (Y.M., C.H.P., R.F.P.); and Memorial Sloan Kettering Cancer Center, New York (D.F.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1613683DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635424PMC
March 2017

From the Guest Editor: The Spectrum of Treatment of Metastatic Prostate Cancer: Present and Future.

Cancer J 2016 Sep/Oct;22(5):321

From the Smilow Cancer Center, Yale School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000224DOI Listing
July 2018

Cancer immunotherapy: new applications in urologic oncology.

Curr Opin Urol 2016 11;26(6):535-42

Yale Cancer Center, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000345DOI Listing
November 2016

A Patient With Pancytopenia, Intractable Epistaxis, and Metastatic Prostate Cancer: How Correct Diagnosis of Primary Hyperfibrinolysis Helps to Stop the Bleeding.

Clin Genitourin Cancer 2016 10 27;14(5):e545-e548. Epub 2016 May 27.

Department of Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.05.002DOI Listing
October 2016

New Agents for the Treatment of Advanced Bladder Cancer.

Oncology (Williston Park) 2016 Jun;30(6):571-9, 588

View Article

Download full-text PDF

Source
June 2016

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

J Clin Oncol 2016 05 7;34(14):1652-9. Epub 2016 Mar 7.

Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.7270
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.7270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872320PMC
May 2016

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

J Clin Oncol 2016 05 29;34(13):1500-9. Epub 2016 Feb 29.

Daniel P. Petrylak, Yale University Cancer Center, New Haven, CT; Scott T. Tagawa, Weill Cornell Medical College, New York; David Shaffer, New York Oncology Hematology, Albany, NY; Manish Kohli, Mayo Clinic, Rochester, MN; Andrea Eisen, Sunnybrook Health Sciences Centre; Srikala S. Sridhar, Princess Margaret Hospital, Toronto; Christina Canil, Ottawa Hospital Cancer Centre, Ottawa, Ontario; Kim N. Chi, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; Alexander Spira, John M. Burke, David Shaffer, and Nicholas J. Vogelzang, US Oncology Research, The Woodlands, TX; Evan Y. Yu, University of Washington Medical Center and Fred Hutchinson Cancer Research Center, Seattle, WA; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; Chong-Xian Pan, University of California-Davis Medical Center, Sacramento; David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Jenny J. Kim, Johns Hopkins University, Baltimore, MD; Jeanny B. Aragon-Ching, George Washington University Medical Center, Washington, DC; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Shande Tang, Hui Zhang, Christopher T. Cavanaugh, Ling Gao, and John S. Kauh, Eli Lilly, Bridgewater, NJ; and Richard A. Walgren, Eli Lilly, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.0218DOI Listing
May 2016

Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.

Can J Urol 2015 Dec;22(6):8048-55

University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

View Article

Download full-text PDF

Source
December 2015

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

J Urol 2015 Dec 18;194(6):1537-47. Epub 2015 Jul 18.

Smilow Cancer Center, Yale University, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2015.06.106DOI Listing
December 2015

Should the Urologist Treat Castration Resistant Prostate Cancer? No.

J Urol 2015 Aug 15;194(2):286-7. Epub 2015 May 15.

Smilow Cancer Center, Yale University, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2015.05.037DOI Listing
August 2015

Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.

J Clin Oncol 2015 Mar 26;33(7):723-31. Epub 2015 Jan 26.

Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif; Stephane Oudard, Université Paris Descartes, Paris, France; Robert Jones, Institute of Cancer Sciences, University of Glasgow, Glasgow; Johann De Bono, The Institute of Cancer Research, London, United Kingdom; Eleni Efstathiou, University of Athens Medical School, Athens; George Fountzilas, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; Fred Saad, University of Montreal Hospital Center, Montreal, Canada; Ronald de Wit, Erasmus University Medical Center, Rotterdam, the Netherlands; Felipe Melo Cruz, ABC Foundation School of Medicine, Santo André; Flavio Carcano, Hospital de Cancer de Barretos, Barretos, Brazil; Albertas Ulys, Institut of Oncology, Vilnius University, Vilnius, Lithuania; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; David Agus, University of Southern California, Los Angeles, CA; Daniel P. Petrylak, Yale University Cancer Center, New Haven, CT; Shih-Yuan Lee, Bindu Tejura, Niels Borgstein, Takeda Pharmaceuticals International; Iain J. Webb, Millennium: The Takeda Oncology Company, Cambridge, MA; Robert Dreicer, Cleveland Clinic, Cleveland, OH; Joaquim Bellmunt, University Hospital del Mar-IMIM, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.56.5119
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.56.5119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879718PMC
March 2015

Could PD-L1 prove to be an effective therapeutic target for bladder cancer?

Immunotherapy 2015 ;7(1):1-2

Yale Comprehensive Cancer Center, Yale School of Medicine, 333 Cedar Street, Fitkin 3, New Haven, CT 06520-8028, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.14.110DOI Listing
September 2015

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

Nature 2014 Nov;515(7528):558-62

University of Nevada School of Medicine and US Oncology/Comprehensive Cancer Centers of Nevada, 3730 S. Eastern Avenue, Las Vegas, Nevada 89169, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature13904DOI Listing
November 2014

Progress in the treatment of advanced prostate cancer.

Am Soc Clin Oncol Educ Book 2014 :117-31

From the San Camillo Forlanini Hospital, Rome, Italy; Yale University Cancer Center, New Haven, CT; Center for Cancer Research, National Cancer Institute, Bethesda, MD; The Royal Marsden Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2014.34.117DOI Listing
November 2015

Practical guide to the use of chemotherapy in castration resistant prostate cancer.

Can J Urol 2014 Apr;21(2 Supp 1):77-83

Yale Cancer Center, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
April 2014

Current management of advanced and castration resistant prostate cancer.

Can J Urol 2014 Apr;21(2 Supp 1):1-6

Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
April 2014

New developments in the treatment of castration resistant prostate cancer.

Asian J Androl 2014 Jul-Aug;16(4):555-60

Department of Medicine, Smilow Cancer Center, Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/1008-682X.127824DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104080PMC
August 2015

Sequencing of agents for castration-resistant prostate cancer.

Oncology (Williston Park) 2013 Nov;27(11):1144-9, 1154-8

Prostate and Urologic Cancers Program, Yale Comprehensive Cancer Center, New Haven, Connecticut 06520, USA.

View Article

Download full-text PDF

Source
November 2013

Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.

Clin Cancer Res 2014 04 17;20(7):1925-34. Epub 2014 Feb 17.

Authors' Affiliations: Royal Marsden NHS Foundation Trust and The Institute of Cancer Research UK, Sutton; Institut Català d'Oncologia, L'Hospitalet, Barcelona; University of Surrey, Surrey, United Kingdom; Yale University Cancer Center, New Haven; Centre Hospitalier de l'Universite de Montreal, Montreal; A Coruña University Hospital, A Coruña, Spain; Kantonsspital St. Gallen, St. Gallen, Switzerland; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Pfizer Inc, Groton, Connecticut; and Lady Davis Institute for Medical Research, Jewish General Hospital and McGill University, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1869DOI Listing
April 2014

Challenges in treating advanced disease.

Am J Manag Care 2013 Dec;19(18 Suppl):s366-75

789 Howard Ave, FMP 312, New Haven, CT 06519. E-mail:

View Article

Download full-text PDF

Source
December 2013

Current state of castration-resistant prostate cancer.

Am J Manag Care 2013 Dec;19(18 Suppl):s358-65

789 Howard Ave, FMP 312, New Haven, CT 06519. E-mail:

View Article

Download full-text PDF

Source
December 2013

The use of serum hCG as a marker of tumor progression and of the response of metastatic urothelial cancer to systemic chemotherapy.

Oncology (Williston Park) 2013 Oct;27(10):1028, 1030

Division of Oncology, Department of Medicine, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
October 2013

The utility of prostate-specific antigen in the management of advanced prostate cancer.

BJU Int 2013 Sep 4;112(5):548-60. Epub 2013 Jul 4.

University of Colorado School of Medicine, Aurora, CO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.12061DOI Listing
September 2013

Tubulin-targeted agents including docetaxel and cabazitaxel.

Cancer J 2013 Jan-Feb;19(1):59-65

Winthrop University Hospital, Mineola, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e3182828d38DOI Listing
July 2013

New therapeutic challenges in advanced bladder cancer.

Semin Oncol 2012 Oct;39(5):598-607

Medical Oncology Service, Parc de Salut Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2012.08.007DOI Listing
October 2012

Role of testosterone in managing advanced prostate cancer.

Urology 2012 Oct 13;80(4):754-62. Epub 2012 Jul 13.

University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2012.05.006DOI Listing
October 2012

Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.

Oncology (Williston Park) 2012 Apr;26(4):330-7, 341

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York 10032, USA.

View Article

Download full-text PDF

Source
April 2012

The role of IMiDs alone or in combination in prostate cancer.

Clin Genitourin Cancer 2012 Sep 17;10(3):141-6. Epub 2012 May 17.

Department of Medicine, Division of Hematology/Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2012.03.005DOI Listing
September 2012

Words of wisdom. Re: Abiraterone and increased survival in metastatic prostate cancer.

Eur Urol 2012 Apr;61(4):850

Division of Oncology, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, New York, NY 10032, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838120009
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2012.01.036DOI Listing
April 2012

New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches.

Urology 2011 Nov;78(5 Suppl):S494-8

Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2011.06.058DOI Listing
November 2011

Evolving therapeutic paradigms for advanced prostate cancer: what's needed to make optimal use of the new treatments.

Oncology (Williston Park) 2011 May;25(6):514-5

Columbia University, New York, New York, USA.

View Article

Download full-text PDF

Source
May 2011

A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer.

Cancer 2012 Jan 29;118(2):358-64. Epub 2011 Jun 29.

Department of Urology, Columbia University Medical Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26278DOI Listing
January 2012